RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease

With the Fast Track designation, RedHill will have access to early and frequent communications with the FDA, to expedite the RHB-204 development program, and to a rolling review of a New Drug Application (NDA).